Rabu, 30 November 2022

Axsome Stock Up Big on Encouraging Alzheimer’s News

Oil up more than $2 on tighter supply but OPEC+ talks limit gains | Amazon records biggest ever Thanksgiving shopping weekend ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Logo

To ensure proper delivery of our emails, please include editor@dailystockbuzz.com within your contact list.

Today's Sponsors

Oil Could Hit $200 a Barrel - Buy This Stock Now

Oil companies are bragging about massive revenue surges, And here’s the craziest part — what we’re seeing today is just the start. Thanks to a convergence of 3 unique market conditions, I believe oil could soar past $180 this year …

Click here to see more.

FDA APPROVAL COULD SEND STOCK UP 113,548%

Whenever the FDA approves a new drug... Timely investors could see 300-400% returns overnight... CCXI returned 281% to investors in one day... Relmada shot up 971% in 9 months... Agile soared 305% in 5 months …

Here's the next stock we think wins approval >>>

Top News

Amazon records biggest ever Thanksgiving shopping weekend

  Nov 30, 2022  

Amazon.com Inc said on Wednesday it recorded its biggest ever Thanksgiving weekend this year as shoppers, undeterred by inflation, scooped up everything from New Balance sneakers to Nintendo Switch gaming consoles ... Read more

Oil up more than $2 on tighter supply but OPEC+ talks limit gains

  Nov 30, 2022  

Oil prices rose by more than $2 on Wednesday on signs of tighter supply, a weaker dollar and optimism over a Chinese demand recovery. But the likelihood that OPEC+ will leave output unchanged at its upcoming meeting limited the gains. ... Read more

Axsome Stock Up Big on Encouraging Alzheimer’s News

  Nov 30, 2022  

All after the company’s “AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer’s disease, as compared to placebo.” ... Read more

Tidak ada komentar:

Posting Komentar